Open Orphan subsidiary secures contract renewal with 'major' pharmaceutical client
Contract research organisation Open Orphan said on Monday that its Venn Life Sciences subsidiary had signed a contract renewal with an unnamed "major global pharmaceutical client" worth £1.5m over a two-year period.
FTSE AIM All-Share
Health Care Equipment & Services
Open Orphan stated the renewed contract would commence in January 2022, with the Venn team set to provide dedicated clinical pharmacokinetics support to the client on |an array of drug development programmes".
Chairman Cathal Friel said: "We are delighted to see this contract renewal signed by the Venn team in Breda with a client that it has been working with since 2012.
"The continued support by Venn to a distinguished partner such as this demonstrates the value of Venn's clinical pharmacokinetics offering, as part of its comprehensive offering in drug development consultancy, clinical trial design and execution."
As of 1130 GMT, Open Orphan shares were up 1.25% at 20.25p.